Metropolis Healthcare Ltd Q4 FY2026 Concall Summary

Key Takeaways

• 14.7% organic revenue growth, no price lever pulled: Patient volumes rose 9.3% and realization improved ~5%, all without a Q4 price increase. The price lever remains available for later in the year.
• Margins expanded structurally, not cyclically: Organic EBITDA margin hit 27.2% in Q4, up from 18.5% a year ago, driven by operating leverage, specialty/wellness mix, and productivity gains that management calls structural rather than one-off.
• Core Diagnostics turned around in 4 quarters: The acquisition moved from negative 2% EBITDA to high-single-digit in Q4 FY26, validating the M&A integration playbook the company now intends to repeat.
• Digital now 25% of revenue, built on a physical brand: Digital channels grew from zero to a quarter of revenue in three years, with lower cost of acquisition and servicing because the brand was already established on the ground.
• What to watch next quarter: Whether the 125–150 bps margin improvement promised for the coming year begins to materialize, the pace of specialty mix shift toward the 40% target, and any price increase decision as the year progresses.

Revenue Growth & Volume Dynamics

• Volume-led growth with realization tailwind: Q4 organic revenue growth of 14.7% split into patient volume growth of 9.3% and realization improvement of ~5%. No price increase was taken in Q4 due to GST reasons, so the realization lift came entirely from mix improvement and better execution.
• Volume outlook sustained: Management is optimistic about sustaining patient volume growth in the 7%–8% range going forward, with an estimated 8%–9% for the coming fiscal. The remaining ~5% of guided growth is expected from realization.
• Price lever held in reserve: The company is not looking at a price increase at this point but would not hesitate if the need arises as the year progresses.
• Mumbai, the largest market, growing in line: Mumbai, with ~500 service centers across the metropolitan area and outskirts, is growing at 13%–14% revenue growth YoY, largely in line with overall volume growth.
• Tier 3 outpacing Tier 1 and 2: Tier 3 cities have been growing at 26%–30% in recent quarters, definitely higher than Tier 1 and Tier 2 on a like-to-like basis. Tier 2 cities like Dehradun and Agra are also showing higher growth, while Tier 1 benefits from Core Diagnostics coming on largely in that setup.

Margin Structure & Productivity

• Organic EBITDA margin expanded ~140 bps for the full year: FY26 organic EBITDA margin reached 25.9% (normalized), with Q4 alone at 27.2% versus 18.5% in the prior-year quarter, which was partly impacted by one-time acquisition-related costs.
• Productivity initiatives now compounding: Lab testing platform upgradation and standardization, equipment vendor consolidation, better inventory discipline through barcoding across all 220 labs, and more optimal use of technology are delivering benefits that started in Q4 and are expected to strengthen over the next two quarters.
• Network build-out phase is over: The heavy capex phase of adding labs and centers is largely behind the company. Lab productivity rose 14% during the year, and no high number of lab additions is planned for the coming year. The center-to-lab ratio improved from 20:1 to 24:1, with a target of 30:1 over 18 months and 35:1 over three years.
• Gross margin improvement levers: Vendor consolidation into higher-efficiency, technology-enabled scalable platforms is giving scale advantage, and barcoding introduced in all labs improved material consumption percentages.
• Steady-state margin philosophy: Management believes a sustainable EBITDA of 27%–28% over the next three years makes sense. If more operating leverage is generated, it will be invested back into the business through added services, brand building, or distribution rather than maximizing EBITDA.

Ameera Shah: "Maximizing the EBITDA may not, in our mind, be a smarter strategy. We believe a sustainable EBITDA of 27% to 28% over the next 3 years makes sense for us. And if we are able to generate more operating leverage, we would like to invest it back in the business, either in terms of adding services or building the brand further, or building further distribution."

Specialty & TruHealth Mix

• Specialty and TruHealth driving mix quality: TruHealth grew 20% in Q4 and 21% for the full year; Specialty grew 17% in Q4 and 16% for the full year. Both categories improved customer engagement and overall mix quality.
• Specialty contribution target of ~40% this year: Two big levers beyond existing specialty testing are expected to push the contribution higher: the genomics journey, which has already started and is accelerating, and the Core Diagnostics product capability being deployed across the network.
• TruHealth can go beyond 25%: The wellness segment has been moving up by a couple of percentage points every year, and management plans to step up efforts to make the shift faster over the next 2–3 years.
• Oncology and neurology are the structural tailwinds: These are the two fastest-growing therapeutic segments globally over the next 10 years, and they will drive more specialty tests toward organized players as consumers and doctors find more comfort in bigger brands with more predictability.

Ameera Shah: "Anyone can add machines, but the real difference in results lies in the personalized interpretation needed for every patient, which rests on institutional expertise and knowledge, not on the equipment."

Digital Channel Economics

• Digital grew from zero to 25% of revenue in three years: Three distinct D2C channels drive this: the Metropolis app, the website for customer test requests, and a customer data platform (CLM engine) that reaches out to existing customers digitally with next-best-action recommendations based on past testing trends.
• Unit economics are brand-backed, not discount-led: Because Metropolis acquires digitally on the back of an already strong physical brand, it enjoys lower cost of acquisition, lower cost of servicing, and higher customer lifetime value. This is not standard for the whole industry, where deep discounting to acquire can produce weak unit economics.
• Margins improve as digital scales: The cost of servicing digital channels is relatively lower than non-digital channels, so margins get better as digital revenue grows.

Ameera Shah: "If you do deep discounting to acquire, then obviously, that business may not have strong unit economics and may not be positive profitably. But the kind of business that Metropolis is acquiring digitally is more on the back of already a strong brand that we have in physical channels on the ground, which allows us to, therefore, have a lower cost of acquisition, a lower cost of servicing, and a higher customer lifetime value."

M&A Integration & Core Diagnostics

• Core Diagnostics turned EBITDA-positive in 4 quarters: The acquisition moved from negative 2% EBITDA to high-single-digit EBITDA in Q4 FY26, meeting the commitment made at the time of the deal.
• Other acquisitions already above company average: The Dehradun, Agra, and Kolhapur acquisitions are operating at margins above the company average. The year was about integration, cleanup, and efficiency, building a repeatable M&A playbook.
• Core on path to 20%-plus EBITDA: The three-year commitment for 20%-plus EBITDA at Core remains on track.
• Inorganic strategy stays selective: Management continues to see opportunities and expects inorganic action for the next few years, but only at the right deal and right price, not just to add growth.
• Reporting simplification from Q1 FY27: Only one consolidated organic number will be shown in the presentation going forward; the prior-year split was provided because acquisitions and integrations were still in progress.

Ameera Shah: "For Core Diagnostics, we have committed that within 4 quarters of doing the acquisition, we would move from a negative 2% EBITDA to a high-single-digit EBITDA in Q4. We have completed this mission."

Network Expansion & Mini-Hubs

• Mini-hubs add radiology to the pathology footprint: The company plans to build a network of 100 mini-hubs over the next three years, with 50 upgraded from existing collection centers and 50 new. These are not just collection centers: they include ECG, X-ray, and in some limited locations sonography, and may include bone density machines, mammography machines, or bigger X-ray equipment. They function as service infrastructure centers for both retail and corporate customers.
• 1,500 more asset-light collection centers over three years: This will take the lab-to-center ratio from 1:24 to the targeted 1:35, with an intermediate goal of 30:1 over the next 18 months. Center productivity is targeted to improve by 20% over the same three-year period.
• Lab utilization rising without new labs: With no more labs being added and more centers feeding the existing network, lab utilization is going up. Management declined to quantify a single utilization rate because labs fall into different categories (big regional reference, global, satellite, greenfield).

Guidance & Commitments

Key Metrics